English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

S everal meta-analyses have shown that the overall outlook for women diagnosed with early breast cancer has improved in recent decades, with better overall survival and fewer relapses. Anthracycline-based therapy, the backbone of early breast cancer treatment, has undoubtedly been a major driving force in those improvements. Yet the drugs also cause long-term heart problems and secondary leukemia in some patients. Researchers are therefore trying to identify equally effective regimens that lack those side effects. Nonanthracycline regimens that have less long-term toxicity may provide equal clinical benefi t in terms of prolonged progression-free and overall survival, according to data presented at the San Antonio Breast Cancer Symposium in December 2007. Given those results and a recently published meta-analysis, some experts are calling for a change in the standard of care: leaving aside anthracyclines. Other breast cancer specialists warn that more trials are needed before the fi eld makes such a major change in care. “Many women could be treated without anthracyclines,” said Stephen Jones, M.D. , director of the breast cancer research center at Baylor Charles A. Sammons Cancer Center and medical director at U.S. Oncology Research in Houston. “The data from the two studies really suggest this is correct,” he said, referring to the data presented in San Antonio.

Anthracycline Therapy May Be Avoidable in Early Breast Cancer, New Studies Suggest